Bao, Guoqiang

He, Xianli

Qiao, Qing

Zhao, Huadong

World Journal of Surgical Oncology

English

PubMed

Guoqiang Bao

Qing Qiao

Huadong Zhao

Xianli He

Springer - Publisher Connector

Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas

Abstract
          
            Introduction
            HMGB1(High mobility group box 1), originally described as a nuclear protein, is now regarded as a multifunctional protein with a paradoxical dual effect in tumors. In the present study, HMGB1 overexpression and its correlation with the clinicopathologic characteristics and recurrence-free survival were evaluated in gastric adenocarcinomas.
          
          
            Methods
            76 gastric adenocarcinomas surgically removed entered the study. The immunohistochemical staining was used to assess HMGB1 expression through tissue microarray procedure. The clinicopathologic characteristics of all patients were recorded, and the regular follow-up was made for all patients.
          
          
            Results
            Almost all the gastric adenocarcinomas showed HMGB1 positive staining mainly in the nucleus, and the overexpression of HMGB1 was found in cancerous tissues with higher strong reactivity rate, compared with non-cancerous tissues (total expression score ≥ 9, 42.0% vs. 9.0%, P &lt; 0.001). Survival analysis revealed that tumor stage negatively correlated with cancer-free survival (P = 0.022). Furthermore, HMGB1 overexpression positively associated with cancer-free survival of resectable gastric adenocarcinomas (P = 0.023).
          
          
            Conclusions
            The overexpression of HMGB1 protein indicates that HMGB1 may play a role in the tumorigenesis of gastric adenocarcinomas. And the overexpression of HMGB1 may be a marker of good prognosis of gastric adenocarcinoma given curative resection combined with adjuvant chemotherapy.
          </jats:sec

Crossref

A: Fibroblasts mediate induction of high mobility group box protein 1 in lung epithelial cancer cells by diffusible factors.

Arumugam T: RAGE and RAGE ligands in cancer. Curr Mol Med

AW: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis

CB: Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus.

DeMarco RA: Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs

DF: V domain of RAGE interacts with AGEs on prostate carcinoma cells. Prostate

Expression of high mobility group box chromosomal protein-1 (HMGB1) in gastric cancer. Anticancer Res

Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin

High mobility group box-1 protein - one step closer to the clinic? Crit Care

High mobility group box-1 protein--one step closer to the clinic? Crit Care

High-mobility group box 1 and cancer.

HJ: High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.

Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut

Inflammation and cancer: a doubleedged sword. Cancer Cell

JB: Serum high mobility group box-1(HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.

KM: High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci USA

Kuniyasu H: HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology

Lotze MT: Masquerader: high mobility group box-1 and cancer. Clin Cancer Res

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res

Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma

Ohmori H: Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages.

Overexpression of highmobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma.

R: RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.

Rouhiainen A: RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease. Curr Mol Med

Rovere-Querini P: HMGB1: a two-headed signal regulating tumor progression and immunity. Curr Opin Immunol

Scandurro AB: Tumors sound the alarmin(s). Cancer Res

Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science

YQ: Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis

Zitvogel L: Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med

Zitvogel L: The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev

Zitvogel L: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med

file:///data/remote/core/dit/data/Springer-OA/pdf/e1a/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTQ3Ny03ODE5LTgtNTIucGRm.pdf

Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Crossref

Springer - Publisher Connector